Pear Ther­a­peu­tics sets the stage for a fruit­ful 2022, fore­cast­ing a five-fold boost in rev­enue

Not so bad for its first earn­ings re­port. In a quar­ter­ly call on Mon­day, Pear Ther­a­peu­tics CEO Corey Mc­Cann cel­e­brat­ed the com­pa­ny’s “strong fi­nan­cial re­sults” since jump­ing on­to Nas­daq last year — work he says will lay the foun­da­tion for an even more fruit­ful year ahead.

Pear $PEAR raked in $4.2 mil­lion last year, com­ing in just above its fore­cast of $4 mil­lion. Ex­ecs tracked a drop in to­tal rev­enue year-over-year due to a one-time col­lab­o­ra­tion pay­ment of $9.2 mil­lion — but the com­pa­ny thinks a 24-fold boost in sales from two of its pre­scrip­tion dig­i­tal ther­a­peu­tics (PDTs) is a good sign of growth to come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER